Cell Cycle Analysis Market Overview
Cell cycle analysis continues to be one of the most important applications developed on the Laser scanning cytometer (LSC) platform. As in fibrillar collagen (FC), the total amount of DNA per cell can precisely and stoichiometrically be determined to obtain cell cycle distributions. Cell cycle analysis products are used in various life science research activities and biomedical research & clinical research laboratories.
Over the past couple of years, due to the increasing number of on cell level research activities, led by the funding support from the private sector and government initiatives the global cell cycle analysis market is growing rapidly. Moreover, factors such as the increasing chronic genetic diseases alongside the rising occurrence of cell-specific diseases and cancer are escalating the market on the global platform.
According to a recently published study report from Market Research Future (MRFR), the global cell cycle analysis market growth has been booming and forecasted to demonstrate a spectacular growth by 2023, registering a striking CAGR throughout the review period (2018 – 2023).
The increasing government expenditure, growth in research and development activities need for early cancer detection, increasing healthcare expenditure are some of the predominant factors fostering the growth of cell cycle analysis market. Additionally, the widening range of application areas and technological advancements in the biotechnology are other factors driving the cell cycle market.
Conversely, lack of skilled professionals and the high costs associated with the instruments and products used in the cell cycle analysis instruments and their maintenance are some of the key factors hindering the growth of the market.
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/673
Cell Cycle Analysis Market- Segments
For ease of understanding, the analysis has been segmented into four key dynamics:
By Product: Consumables and Instruments among others.
By Application : Cell Identification, Cell Viability, Cell Signaling Pathway/Signal Transduction, Cell Proliferation, Cell Counting & Quality Control, Cell Interaction, Cell Structure Study, Target Identification, and Validation & Single-Cell Analysis among others.
By End-user: Academics & Research Institutions, Hospitals & Diagnostic Laboratories, and Pharmaceuticals (CROs and biotechnology companies) among other end-users.
By Region: North America, Europe, Asia Pacific, and the Rest-of-the-World.
Global Cell Cycle Analysis Market- Regional Analysis
The North American region, heading with the presence of well-established research and development facilities dominates the global cell cycle analysis market. Additional factors such as the increasing R&D activities led by the constant support and funding from the government as well as private organizations are positively impacting the growth of the market. Rising prevalence of cancer is also a key driving force behind the growth of the market.
Increasing clinical trials, drug discovery activities, and upgrading technological advancements such as CGH and Chip-on-chip are encouraging the growth in the regional market. Widening application areas of the cell cycle are expected to develop new market opportunities for the growth in the region. Moreover, increasing mergers and acquisition, growing collaborations and partnerships, and product launches are some of the latest trends in the regional market.
The cell cycle analysis market in the European region accounts for the second-largest market, globally. Increasing technological advancement, improved healthcare industries, growing research & development activities in life sciences and medical research institutes are the major growth driving factors for the cell cycle analysis market in Europe. Moreover, increased usage of personalized medicines, increasing cancer incidences and growing government support are propelling the growth of the market.
The Asia Pacific cell cycle analysis market is emerging as a profitable market, globally. The growing prevalence of chronic diseases, improving healthcare infrastructure, increasing government expenditure, and increasing drug discovery activities are the major growth drivers. China and India are the emerging economies due to the improved lifestyle, growing awareness about biological terms and its benefits and government support the APAC region.
In India, top pharma companies are now partly foreign-owned and are already generating more than half of their sales outside the country. Besides this, economic growth has increased the buying power of India’s middle-income group for healthcare services in general, particularly medicines. The emergence of lifestyle diseases such as diabetes, cardiovascular disease, and cancer has increased the demand for medicines.
Global Cell Cycle Analysis Market- Competitive Analysis
The cell cycle analysis market appears highly competitive and fragmented characterized by the presence of several well-established and small players. Well-established players incorporate strategic initiatives such as acquisition, collaboration, partnership, expansion, and product launch to gain an edge over their competitions and thus to maintain their positions in the market. These players compete based on pricing, availability, brand, and variety.
Cell Cycle Analysis Market Major Players:
Key players leading the global cell cycle analysis market include Becton, Dickinson and Company, Merck & Co., Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, GE Healthcare, Agilent Technologies, Inc., Olympus Corporation, PerkinElmer, Inc., Promega Corporation, Bio-Rad Laboratories, Inc., Miltenyi Biotech, and Nexcelom Bioscience LLC among others.
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/cell-cycle-analysis-market-673
Cell Cycle Analysis Industry/ Innovation/ Related News:
March 21, 2019 —– A group of scientists at the UNC School of Medicine and the UNC Lineberger Comprehensive Cancer Center (the US) announced the discovery of a possible reason why Basal-like breast cancer is the most aggressive & difficult-to-treat. Today, patients are in dire need of improved therapies that attack the underlying cellular features of these types of breast cancer.
In lab experiments, these researchers found that an enzyme called USP21 promoted the proliferation of basal-like breast cancer and is up-regulated in a significant percentage of patient tumors.
Despite the importance of FOXM1, a transcription factor crucial for the proper completion of the cell cycle and cell proliferation in normal and cancer cell cycles, scientists have lacked a complete understanding of the mechanisms that regulate FOXM1. The discovery will offer researchers a much-needed target for new therapies to battle aggressive subtypes of breast cancer.